We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Arecor Therapeutics Plc | LSE:AREC | London | Ordinary Share | GB00BMWLM973 | ORD GBP0.01 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 137.50 | 135.00 | 140.00 | 137.50 | 137.50 | 137.50 | 17,518 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 3.54M | -9.26M | -0.3024 | -4.55 | 42.11M |
From May 2021 to May 2024
By Jaime Llinares Taboada
Shares in Arecor Therapeutics PLC climbed Monday morning after its polysaccharide vaccine patent was upheld by the European Patent Office.
The EPO was considering an appeal filed by GlaxoSmithKline PLC, but this was dismissed.
Arecor said its patent protects novel compositions of a specific type of vaccines, called polysaccharide vaccines, which are used to prevent degradation.
Polysaccharide vaccines are used to protect against diseases such as meningitis and pneumonia.
Shares at 0855 GMT were up 9.2% at 415 pence.
Write to Jaime Llinares Taboada at jaime.llinares@wsj.com; @JaimeLlinaresT
(END) Dow Jones Newswires
October 11, 2021 05:19 ET (09:19 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Arecor Therapeutics Chart |
1 Month Arecor Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
